Drugs (including oxygen) in severe COPD

European Respiratory Journal

Volumn 31, Issue 5, 2008, Pages 1114-1124

  Albert, P ^a   Calverley, P M A ^a  

^a UNIVERSITY HOSPITAL AINTREE   (United Kingdom)

Author keywords

Chronic obstructive pulmonary disease; Combining; Drug therapy; Exacerbation; Oxygen

Indexed keywords

ACETYLCYSTEINE; AMFEBUTAMONE; AMINOPHYLLINE; ANTIBIOTIC AGENT; BECLOMETASONE DIPROPIONATE; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE; CARBOCISTEINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CICLESONIDE; CORTICOSTEROID; ERDOSTEINE; FLUTICASONE PROPIONATE; FORMOTEROL; HYDROCORTISONE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IPRATROPIUM BROMIDE; MECYSTEINE; MOMETASONE FUROATE; OFLOXACIN; PREDNISOLONE; SALBUTAMOL; SALMETEROL; STEROID; TERBUTALINE; THEOPHYLLINE; TIOTROPIUM BROMIDE; TRIAMCINOLONE ACETONIDE; VARENICLINE;

ARTERIAL OXYGEN TENSION; CATARACT; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; CONVULSION; DISEASE EXACERBATION; EXERCISE; HEALTH STATUS; HEART VENTRICLE TACHYCARDIA; HUMAN; LUNG MECHANICS; MORTALITY; OSTEOPOROSIS; OUTCOME ASSESSMENT; OXYGEN THERAPY; PATIENT CARE; PNEUMONIA; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; EXERCISE TOLERANCE; MULTIMODALITY CANCER THERAPY;

ADRENAL CORTEX HORMONES; ADRENERGIC BETA-AGONISTS; CHOLINERGIC ANTAGONISTS; COMBINED MODALITY THERAPY; EXERCISE TOLERANCE; HUMANS; OXYGEN INHALATION THERAPY; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

EID: 47049104141     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00116707     Document Type: Review

References (100)

1. The National Collaborating Centre for Chronic Conditions, Chronic obstructive pulmonary disease. National clinical guideline on management of chronic obstructive pulmonary disease in adults in primary and secondary care. Thorax 2004; 59: Suppl. 1, i1-i232.
2. Rabe KF, Hurd S, Anzueto A, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2007; 176: 532-555.
3. Celli BR, MacNee W. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 2004; 23: 932-946.
4. Soler-Cataluna JJ, Martinez-Garcia MA, Roman SP, Salcedo E, Navarro M, Ochando R. Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. Thorax 2005; 60: 925-931.
5. Stevenson NJ, Walker PP, Costello RW, Calverley PM. Lung mechanics and dyspnea during exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2005; 172: 1510-1516.
6. Parker CM, Voduc N, Aaron SD, Webb KA, O'Donnell DE. Physiological changes during symptom recovery from moderate exacerbations of COPD. Eur Respir J 2005; 26: 420-428.
7. Plant PK, Elliott MW. Chronic obstructive pulmonary disease: management of ventilatory failure in COPD. Thorax 2003; 58: 537-542.
8. Costello RW, Liston R, McNicholas WT. Compliance at night with low flow oxygen therapy: a comparison of nasal cannulae and Venturi face masks. Thorax 1995; 50: 405-406.
9. Bazuaye EA, Stone TN, Corris PA, Gibson GJ. Variability of inspired oxygen concentration with nasal cannulas. Thorax 1992; 47: 609-611.
10. Hadcroft J, Calverley PM. Alternative methods for assessing bronchodilator reversibility in chronic obstructive pulmonary disease. Thorax 2001; 56: 713-720.
11. Barr RG, Rowe BH, Camargo CA Jr. Methylxanthines for exacerbations of chronic obstructive pulmonary disease: meta-analysis of randomised trials. BMJ 2003; 327: 643.
12. Duffy N, Walker P, Diamantea F, Calverley P, Davies L. Intravenous aminophylline in patients admitted to hospital with exacerbations of chronic obstructive pulmonary disease: a prospective randomised controlled trial. Thorax 2005; 60: 713-717.
13. Lightowler JV, Wedzicha JA, Elliott MW, Ram FS. Noninvasive positive pressure ventilation to treat respiratory failure resulting from exacerbations of chronic obstructive pulmonary disease: Cochrane systematic review and meta-analysis. BMJ 2003; 326: 185.
14. Saint S, Bent S, Vittinghoff E, Grady D. Antibiotics in chronic obstructive pulmonary disease exacerbations. A meta-analysis. JAMA 1995; 273: 957-960.
15. Nouira S, Marghli S, Belghith M, Besbes L, Elatrous S, Abroug F. Once daily oral ofloxacin in chronic obstructive pulmonary disease exacerbation requiring mechanical ventilation: a randomised placebo-controlled trial. Lancet 2001; 358: 2020-2025.
16. Davies L, Angus RM, Calverley PMA. Oral corticosteroids in patients admitted to hospital with exacerbations of chronic obstructive pulmonary disease: a prospective randomised controlled trial. Lancet 1999; 354: 456-460.
17. Niewoehner DE, Erbland ML, Deupree RH, et al. Effect of systemic glucocorticoids on exacerbations of chronic obstructive pulmonary disease. N Engl J Med 1999; 340: 1941-1947.
18. Gorecka D, Bednarek M, Nowinski A, Puscinska E, Goljan-Geremek A, Zielinski J. Diagnosis of airflow limitation combined with smoking cessation advice increases stop-smoking rate. Chest 2003; 123: 1916-1923.
19. Bednarek M, Gorecka D, Wielgomas J, et al. Smokers with airway obstruction are more likely to quit smoking. Thorax 2006; 61: 869-873.
20. Anthonisen NR, Skeans MA, Wise RA, Manfreda J, Kanner RE, Connett JE. The effects of a smoking cessation intervention on 14.5-year mortality: a randomized clinical trial. Ann Intern Med 2005; 142: 233-239.
21. Tashkin D, Kanner R, Bailey W, et al. Smoking cessation in patients with chronic obstructive pulmonary disease: a double-blind, placebo-controlled, randomised trial. Lancet 2001; 357: 1571-1575.
22. Jorenby DE, Hays JT, Rigotti NA, et al. Efficacy of varenicline, an α4β2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. JAMA 2006; 296: 56-63.
23. Vestbo J, Sorensen T, Lange P, Brix A, Torre P, Viskum, Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 1999; 353: 1819-1823.
24. Pauwels RA, Lofdahl C-G, Laitinen LA, et al. Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. New Engl J Med 1999; 340: 1948-1953.
25. The Lung Health Study Research Group. Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease. N Engl J Med 2000; 343: 1902-1909.
26. Burge PS, Calverley PM, Jones PW, Spencer S, Anderson JA, Maslen TK. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ 2000; 320: 1297-1303.
27. 1 decline in COPD patients randomized to inhaled corticosteroids or placebo. Chest 2007; 131: 682-689.
28. Sutherland ER, Allmers H, Ayas NT, Venn AJ, Martin RJ. Inhaled corticosteroids reduce the progression of airflow limitation in chronic obstructive pulmonary disease: a meta-analysis. Thorax 2003; 58: 937-941.
29. Celli B, Ferguson GT, Anderson JA, et al. Salmeterol/fluticasone propionate (SFC) improves lung function and reduces rate of decline over three years in the TORCH survival study. Proc Am Thorac Soc 2007; 4: Suppl. 2, A763.
30. Rennard SI, Calverley P. Rescue! Therapy and the paradox of the Barcalounger. Eur Respir J 2003; 21: 916-917.
31. Calverley PM, Lee A, Towse L, van Noord J, Witek TJ, Kelsen S. Effect of tiotropium bromide on circadian variation in airflow limitation in chronic obstructive pulmonary disease. Thorax 2003; 58: 855-860.
32. Casaburi R, Mahler DA, Jones PW, et al. A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur Respir J 2002; 19: 217-224.
33. Stockley RA, Chopra N, Rice L. Addition of salmeterol to existing treatment in patients with COPD: a 12 month study. Thorax 2006; 61: 122-128.
34. McKay SE, Howie CA, Thomson AH, Whiting B, Addis GJ. Value of theophylline treatment in patients handicapped by chronic obstructive lung disease. Thorax 1993; 48: 227-232.
35. Calverley P, Pauwels R, Vestbo J, et al. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 2003; 361: 449-456.
36. Calverley PM, Boonsawat W, Cseke Z, Zhong N, Peterson S, Olsson H. Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. Eur Respir J 2003; 22: 912-919.
37. Calverley PM, Anderson JA, Celli B, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007; 356: 775-789.
38. Celli B, ZuWallack R, Wang S, Kesten S. Improvement in resting inspiratory capacity and hyperinflation with tiotropium in COPD patients with increased static lung volumes. Chest 2003; 124: 1743-1748.
39. O'Donnell DE, Lam M, Webb KA. Spirometric correlates of improvement in exercise performance after anticholinergic therapy in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999; 160: 542-549.
40. Celli BR, Cote CG, Marin JM, et al. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med 2004; 350: 1005-1012.
41. Oga T, Nishimura K, Tsukino M, Sato S, Hajiro T. Analysis of the factors related to mortality in chronic obstructive pulmonary disease: role of exercise capacity and health status. Am J Respir Crit Care Med 2003; 167: 544-549.
42. Hay JG, Stone P, Carter J, et al. Bronchodilator reversibility, exercise performance and breathlessness in stable chronic obstructive pulmonary disease. Eur Respir J 1992; 5: 659-664.
43. O'Donnell DE, Voduc N, Fitzpatrick M, Webb KA. Effect of salmeterol on the ventilatory response to exercise in chronic obstructive pulmonary disease. Eur Respir J 2004; 24: 86-94.
44. O'Donnell DE, Fluge T, Gerken F, et al. Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD. Eur Respir J 2004; 23: 832-840.
45. Man WD, Mustfa N, Nikoletou D, et al. The effect of salmeterol on respiratory muscle activity during exercise in poorly reversible COPD. Thorax. 2004; 59: 471-476.
46. Aliverti A, Rodger K, Dellaca RL, et al. Effect of salbutamol on lung function and chest wall volumes at rest and during exercise in COPD. Thorax 2005; 60: 916-924.
47. O'Donnell DE, Sciurba F, Celli B, et al. Effect of fluticasone propionate/salmeterol on lung hyperinflation and exercise endurance in COPD. Chest 2006; 130: 647-656.
48. Jones PW, Willits LR, Burge PS, Calverley PM. Disease severity and the effect of fluticasone propionate on chronic obstructive pulmonary disease. Eur Respir J 2003; 21: 68-73.
49. Spencer S, Calverley PM, Burge PS, Jones PW. Impact of preventing exacerbations on deterioration of health status in COPD. Eur Respir J 2004; 23: 698-702.
50. Sethi S, Maloney J, Grove L, Wrona C, Berenson CS. Airway inflammation and bronchial bacterial colonization in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2006; 173: 991-998.
51. Sethi S, Evans N, Grant BJ, Murphy TF. New strains of bacteria and exacerbations of chronic obstructive pulmonary disease. N Engl J Med 2002; 347: 465-471.
52. Seemungal TA, Wilkinson TM, Perera WR, Hurst JR, Wedzicha JA. Long term macrolide therapy decreases exacerbations in COPD. Proc Am Thorac Soc 2007; 4: Suppl. 2, A764.
53. Niewoehner DE, Rice K, Cote C, et al. Prevention of exacerbations of chronic obstructive pulmonary disease with tiotropium, a once-daily inhaled anticholinergic bronchodilator: a randomized trial. Ann Intern Med 2005; 143: 317-326.
54. Calverley PM. The role of corticosteroids in chronic obstructive pulmonary disease. Semin Respir Crit Care Med 2005; 26: 235-245.
55. Suissa S. Statistical treatment of exacerbations in therapeutic trials of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2006; 173: 842-846.
56. Szafranski W, Cukier A, Ramirez A, et al. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. Eur Respir J 2003; 21: 74-81.
57. Stey C, Steurer J, Bachmann S, Medici TC, Tramer MR. The effect of oral N-acetylcysteine in chronic bronchitis: a quantitative systematic review. Eur Respir J 2000; 16: 253-262.
58. Poole P, Black P. Oral mucolytic drugs for exacerbations of chronic obstructive pulmonary disease: systematic review. BMJ 2001; 322: 1271.
59. Decramer M, Rutten-van Molken M, Dekhuijzen PN, et al. Effects of N-acetylcysteine on outcomes in chronic obstructive pulmonary disease (Bronchitis Randomized on NAC Cost-Utility Study, BRONCUS): a randomised placebo-controlled trial. Lancet 2005; 365: 1552-1560.
60. Spencer S, Jones PW. Time course of recovery of health status following an infective exacerbation of chronic bronchitis. Thorax 2003; 58: 589-593.
61. Jones PW. Interpreting thresholds for a clinically significant change in health status in asthma and COPD. Eur Respir J 2002; 19: 398-404.
62. McGarvey LP, John M, Anderson JA, Zvarich MT, Wise RA. Ascertainment of cause-specific mortality in COPD - operations of the TORCH Clinical Endpoint Committee. Thorax 2007; 62: 411-415.
63. Jensen HH, Godtfredsen NS, Lange P, Vestbo J. Potential misclassification of causes of death from COPD. Eur Respir J 2006; 28: 781-785.
64. La Vecchia C, Fabbri LM. Prevention of death in COPD. N Engl J Med 2007; 356: 2211-2212.
65. Fuld JP, Kilduff LP, Neder JA, et al. Creatine supplementation during pulmonary rehabilitation in chronic obstructive pulmonary disease. Thorax 2005; 60: 531-537.
66. Casaburi R, Bhasin S, Cosentino L, et al. Effects of testosterone and resistance training in men with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2004; 170: 870-878.
67. Steiner MC, Barton RL, Singh SJ, Morgan MD. Nutritional enhancement of exercise performance in chronic obstructive pulmonary disease: a randomised controlled trial. Thorax 2003; 58: 745-751.
68. Bolton CE, Ionescu AA, Shiels KM, et al. Associated loss of fat-free mass and bone mineral density in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2004; 170: 1286-1293.
69. Sabit R, Bolton CE, Edwards PH, et al. Arterial stiffness and osteoporosis in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007; 175: 1259-1265.
70. Frost FJ, Petersen H, Tollestrup K, Skipper B. Influenza and COPD mortality protection as pleiotropic, dose-dependent effects of statins. Chest 2007; 131: 1006-1012.
71. Soyseth V, Brekke PH, Smith P, Omland T. Statin use is associated with reduced mortality in COPD. Eur Respir J 2007; 29: 279-283.
72. Mancini GB, Etminan M, Zhang B, Levesque LE, FitzGerald JM, Brophy JM. Reduction of morbidity and mortality by statins, angiotensin-converting enzyme inhibitors, and angiotensin receptor blockers in patients with chronic obstructive pulmonary disease. J Am Coll Cardiol 2006; 47: 2554-2560.
73. Kesten S, Jara M, Wentworth C, Lanes S. Pooled clinical trial analysis of tiotropium safety. Chest 2006; 130: 1695-1703.
74. Ernst P, Gonzalez AV, Brassard P, Suissa S. Inhaled corticosteroid use in chronic obstructive pulmonary disease and the risk of hospitalization for pneumonia. Am J Respir Crit Care Med 2007; 176: 162-166.
75. Long term domiciliary oxygen therapy in chronic hypoxic cor pulmonale complicating chronic bronchitis and emphysema, Report of the Medical Research Council Working Party. Lancet 1981; 1: 681-686.
76. Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease, a clinical trial. Nocturnal Oxygen Therapy Trial Group. Ann Intern Med 1980; 93: 391-398.
77. Gorecka D, Gorzelak K, Sliwinski P, Tobiasz M, Zielinski J. Effect of long-term oxygen therapy on survival in patients with chronic obstructive pulmonary disease with moderate hypoxaemia. Thorax 1997; 52: 674-679.
78. 2 desaturation and daytime pulmonary haemodynamics in COPD patients with mild hypoxaemia. Eur Respir J 1997; 10: 1730-1735.
79. Nisbet M, Eaton T, Lewis C, Fergusson W, Kolbe J. Overnight prescription of oxygen in long term oxygen therapy: time to reconsider the guidelines? Thorax 2006; 61: 779-782.
80. Whipp BJ. Carotid bodies and breathing in humans. Thorax 1994; 49: 1081-1084.
81. O'Donnell DE, Bain DJ, Webb KA. Factors contributing to relief of exertional breathlessness during hyperoxia in chronic airflow limitation. Am J Respir Crit Care Med 1997; 155: 530-535.
82. O'Donnell DE, D'Arsigny C, Webb KA. Effects of hyperoxia on ventilatory limitation during exercise in advanced chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001; 163: 892-898.
83. Somfay A, Porszasz J, Lee SM, Casaburi R. Dose-response effect of oxygen on hyperinflation and exercise endurance in nonhypoxaemic COPD patients. Eur Respir J 2001; 18: 77-84.
84. Calverley PM, Leggett RJ, Flenley DC. Carbon monoxide and exercise tolerance in chronic bronchitis and emphysema. BMJ 1981; 283: 878-880.
85. Laude EA, Duffy NC, Baveystock C, et al. The effect of helium and oxygen on exercise performance in COPD: a randomised crossover trial. Am J Respir Crit Care Med 2006; 173: 865-870.
86. Eaton T, Garrett JE, Young P, et al. Ambulatory oxygen improves quality of life of COPD patients: a randomised controlled study. Eur Respir J 2002; 20: 306-312.
87. Lacasse Y, Lecours R, Pelletier C, Begin R, Maltais F. Randomised trial of ambulatory oxygen in oxygen-dependent COPD. Eur Respir J 2005; 25: 1032-1038.
88. Spence DP, Graham DR, Ahmed J, Rees K, Pearson MG, Calverley PM. Does cold air affect exercise capacity and dyspnea in stable chronic obstructive pulmonary disease? Chest 1993; 103: 693-696.
89. Schwartzstein RM, Lahive K, Pope A, Weinberger SE, Weiss JW. Cold facial stimulation reduces breathlessness induced in normal subjects. Am Rev Respir Dis 1987; 136: 58-61.
90. Woodcock AA, Gross ER, Geddes DM. Oxygen relieves breathlessness in "pink puffers". Lancet 1981; 1: 907-909.
91. Stevenson NJ, Calverley PM. Effect of oxygen on recovery from maximal exercise in patients with chronic obstructive pulmonary disease. Thorax 2004; 59: 668-672.
92. Nandi K, Smith AA, Crawford A, et al. Oxygen supplementation before or after submaximal exercise in patients with chronic obstructive pulmonary disease. Thorax 2003; 58: 670-673.
93. Eaton T, Fergusson W, Kolbe J, Lewis CA, West T. Short-burst oxygen therapy for COPD patients: a 6-month randomised, controlled study.Eur Respir J 2006; 27: 697-704.
94. In chronic obstructive pulmonary disease, a combination of ipratropium and albuterol is more effective than either agent alone, An 85-day multicenter trial. COMBIVENT Inhalation Aerosol Study Group. Chest 1994; 105: 1411-1419.
95. Van Noord JA, Aumann JL, Jansseens E, et al. Comparison of tiotropium qd, formoterol bid and both combined qd in patients with COPD. Eur Respir J 2005; 26: 214-222.
96. Aaron SD, Vandemheen KL, Fergusson D, et al. Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. Ann Intern Med 2007; 148: 545-555.
97. Zuwallack RL, Mahler DA, Reilly D, et al. Salmeterol plus theophylline combination therapy in the treatment of COPD. Chest 2001; 119: 1661-1670.
98. Zhou Y, Wang X, Zeng X, et al. Positive benefits of theophylline in a randomized, double-blind, parallel-group, placebo-controlled study of low-dose, slow-release theophylline in the treatment of COPD for 1 year. Respirology 2006; 11: 603-610.
99. Peters MM, Webb KA, O'Donnell DE. Combined physiological effects of bronchodilators and hyperoxia on exertional dyspnoea in normoxic COPD. Thorax 2006; 61: 559-567.
100. Cukier A, Ferreira CA, Stelmach R, Ribeiro M, Cortopassi F, Calverley PM. The effect of bronchodilators and oxygen alone and in combination on self-paced exercise performance in stable COPD. Respir Med 2007; 101: 746-753.